Brief: Elicera Therapeutics Q2 Operating Loss At SEK 2.89 Mln
29/08/2025 07:21
Aug 29 (Reuters) - Elicera Therapeutics AB ELIC.ST: Q2 ADJUSTED EPS SEK -0.06 OPERATING LOSS FOR Q2 2025 AMOUNTED TO SEK -2,892,341 Source text: ID:nWkr2Frdrg Further company coverage: ELIC.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent